N
CNCE

Nuveen’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Nuveen’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-277,611
Closed -$1.39M – 3594
2021
Q1 		$1.39M Sell
277,611
-10,299
-4% -$83.2K ﹤0.01% 2775
2020
Q4 		$3.64M Sell
287,910
-906
-0.3% -$10.3K ﹤0.01% 2229
2020
Q3 		$2.84M Sell
288,816
-50,933
-15% -$502K ﹤0.01% 2210
2020
Q2 		$3.38M Sell
339,749
-43,286
-11% -$415K ﹤0.01% 2100
2020
Q1 		$3.39M Buy
383,035
+54,077
+16% +$533K ﹤0.01% 1917
2019
Q4 		$3.04M Sell
328,958
-115,412
-26% -$818K ﹤0.01% 2237
2019
Q3 		$2.61M Sell
444,370
-15,852
-3% -$168K ﹤0.01% 2281
2019
Q2 		$5.52M Buy
+460,222
New +$4.95M ﹤0.01% 1930

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Nuveen's CNCE Position: Q2 2021 in Review

Nuveen sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 277,611 shares — an estimated $1.39M sold.

Nuveen first reported a position in CNCE in Q2 2019 and held it in 8 quarters. The position peaked at $5.52M in Q2 2019. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

  • Nuveen reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 277,611 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1.39M.
  • Nuveen first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 8 quarters.
  • Nuveen's Concert Pharmaceuticals, Inc. position peaked at $5.52M in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.